An update from Nkarta ( (NKTX) ) is now available.
On March 26, 2025, Nkarta announced a significant restructuring plan, including a 34% reduction in its workforce, to streamline operations and focus resources on the development of NKX019 for autoimmune diseases. This strategic move is expected to extend the company’s cash runway into 2029 and ensure financial stability to achieve key clinical milestones, with preliminary data from ongoing trials anticipated in the second half of 2025. The company also announced the transition of its Chief Financial and Business Officer, Alyssa Levin, who will continue as a consultant post-termination, and the appointment of Nadir Mahmood as the new principal financial officer. These changes are part of Nkarta’s efforts to maintain its competitive position in the evolving landscape of cellular therapies for autoimmune diseases.
More about Nkarta
Nkarta is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. The company leverages its cell expansion and cryopreservation platform along with proprietary cell engineering technologies to build a pipeline of future cell therapies.
YTD Price Performance: -42.80%
Average Trading Volume: 1,023,844
Technical Sentiment Signal: Buy
Current Market Cap: $100.9M
For detailed information about NKTX stock, go to TipRanks’ Stock Analysis page.